Improving Access to Alternative Therapies for Treatment Resistant Depression

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.

Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.

Dr Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to accessing care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies, and explain barriers within the health care system that inhibit access.

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD, including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Key opinion leaders discuss navigation through challenges with appropriate coding for the treatment of patients with treatment-resistant depression.

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for treatment-resistant depression along with implications to patients.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for treatment-resistant depression.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in treatment-resistant depression, as well as alternative payment models.

An expert panel shares insight on the future treatment landscape for treatment-resistant depression.